Covered recipient · General Payments record
AUSTIN A HOWARD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$4,948.90
- Reported across 371 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $188.17 | 11 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $47.47 | 3 |
| ABBVIE INC. | $43.66 | 2 |
| GlaxoSmithKline, LLC. | $28.03 | 2 |
| Novo Nordisk AS | $22.19 | 1 |
| Merck Sharp & Dohme Corporation | $17.48 | 1 |
| Amgen Inc. | $16.07 | 1 |
| SANOFI-AVENTIS U.S. LLC | $13.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.69 | 07/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997505737 | CMS |
| ABBVIE INC. | $20.97 | 07/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997505739 | CMS |
| Amgen Inc. | $16.07 | 06/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1020540889 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.83 | 02/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015364823 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.32 | 02/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015420013 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.32 | 03/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1011682861 | CMS |
| GlaxoSmithKline, LLC. | $14.76 | 02/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1002984328 | CMS |
| GlaxoSmithKline, LLC. | $13.27 | 05/29/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1002984343 | CMS |
| Merck Sharp & Dohme LLC | $17.48 | 04/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1048932239 | CMS |
| Novo Nordisk Inc | $22.19 | 06/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001454325 | CMS |
| SANOFI-AVENTIS U.S. LLC | $13.27 | 03/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050272169 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.